UpdatesPlus-Nicotinic Receptors (January 2008)
The January edition of UpdatesPlus-Nicotinic Receptors has now been published.
Providing a detailed view of all key information from the exciting and rapidly expanding field of neuronal nicotinic receptors, this service is a must to all involved in CNS drug development.
UpdatesPlus is available as a yearly subscription.
Subscribe now and receive the next 12 monthly editions plus our recent report:
What's in the January 2008 edition of UpdatesPlus-Nicotinic Receptors
The January 2008 edition of UpdatesPlus-Nicotinic Receptors reports on key events identified through tracking of:
- Journal Publications
- Clinical Trials
- Company Press Releases
- Investor presentations
This month, as usual we provide a fully up to date snapshot of the nicotinic receptor ligand pipeline. In addition we report on breaking activity:
- Memory Pharmaceuticals' phase 2a study of MEM 3454 in CIAS
- Research activity from within Abbott researchers focussing on a novel series of α7 agonists
- Movement from within Italian biotech, Siena toward the identification of nicotinic candidates
- Breaking data to support the development of nicotinic receptor ligands as treatments of lung cancer
- New efforts to validate varenicline (Chantix) as a candidate treatment of cocaine addiction
- Pfizer change label for Chantix in reponse to safety issues
- A NeuroSearch pipeline update
- Preclinical research describing the potential of ABT-894 as a treatment of visceral pain
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: nicotinic alzheimer's cias schizophrenia schizoaffective nicotinic 2008 receptor pain receptors updatesplus abt894 receptors schizophrenia abt
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.